These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24147530)

  • 1. Early evaluation and value-based pricing of regenerative medicine technologies.
    Koerber F; Rolauffs B; Rogowski W
    Regen Med; 2013 Nov; 8(6):747-58. PubMed ID: 24147530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine.
    de Windt TS; Sorel JC; Vonk LA; Kip MMA; Ijzerman MJ; Saris DBF
    J Tissue Eng Regen Med; 2017 Oct; 11(10):2950-2959. PubMed ID: 27401932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regenerative medicine: learning from past examples.
    Couto DS; Perez-Breva L; Cooney CL
    Tissue Eng Part A; 2012 Nov; 18(21-22):2386-93. PubMed ID: 22697402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The strong financial case for regenerative medicine and the regen industry.
    Mason C; Dunnill P
    Regen Med; 2008 May; 3(3):351-63. PubMed ID: 18462058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic value of investing in regenerative medicine.
    Hussain A; Rivers PA
    J Health Care Finance; 2009; 36(2):45-54. PubMed ID: 20499720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
    Hartz S; John J
    Int J Technol Assess Health Care; 2008; 24(4):465-72. PubMed ID: 18828942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
    Rose JB; Williams DJ
    Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
    Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S
    Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation in cardiology.
    Maniadakis N; Vardas P; Mantovani LG; Fattore G; Boriani G
    Europace; 2011 May; 13 Suppl 2():ii3-8. PubMed ID: 21518746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
    Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
    J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cells and regenerative medicine on the Asian horizon: an economic, industry and social perspective.
    Sipp D
    Regen Med; 2009 Nov; 4(6):911-8. PubMed ID: 19903008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue engineering and regenerative medicine: history, progress, and challenges.
    Berthiaume F; Maguire TJ; Yarmush ML
    Annu Rev Chem Biomol Eng; 2011; 2():403-30. PubMed ID: 22432625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regenerative medicine. The industry comes of age.
    Mason C
    Med Device Technol; 2007; 18(2):25-30. PubMed ID: 17494498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.